(VIANEWS) – ELIS (ELIS.PA), ZALARIS (ZAL.OL), BOUVET (BOUV.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ELIS (ELIS.PA)
77.2% sales growth and 7.22% return on equity
Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. The company was founded in 1883 and is headquartered in Saint-Cloud, France.
Earnings Per Share
As for profitability, ELIS has a trailing twelve months EPS of €1.06.
PE Ratio
ELIS has a trailing twelve months price to earnings ratio of 19.87. Meaning, the purchaser of the share is investing €19.87 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.22%.
Sales Growth
ELIS’s sales growth for the next quarter is 77.2%.
Yearly Top and Bottom Value
ELIS’s stock is valued at €21.06 at 02:20 EST, way under its 52-week high of €23.58 and way above its 52-week low of €14.96.
Moving Average
ELIS’s worth is higher than its 50-day moving average of €20.49 and above its 200-day moving average of €20.79.
More news about ELIS.
2. ZALARIS (ZAL.OL)
11.7% sales growth and 17.45% return on equity
Zalaris ASA provides full-service outsourced personnel and payroll services. It operates in two segments, Managed Services and Professional Services. The company offers a range of payroll and human resource (HR) outsourcing services, including payroll processing, time and attendance, and travel expenses, as well as cloud-based HR functionality services comprising talent management, digital personnel archive, HR analytics, mobile solutions, etc. It also engages in the implementation of SAP HCM, and Payroll and SuccessFactors; and provides consulting services. The company serves bank, insurance and financial services, health and life science, infrastructure and transportation, IT, technology and telecom, offshore and energy, products and industrials, retail, and service industries, as well as public services and other institutions. It operates in Norway, Sweden, Denmark, Germany, Finland, the United Kingdom, Latvia, Poland, Australia, and internationally. The company was formerly known as Zalaris HR Services AS and changed its name to Zalaris ASA in May 2014. Zalaris ASA was incorporated in 2000 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ZALARIS has a trailing twelve months EPS of kr2.41.
PE Ratio
ZALARIS has a trailing twelve months price to earnings ratio of 28.46. Meaning, the purchaser of the share is investing kr28.46 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.45%.
Yearly Top and Bottom Value
ZALARIS’s stock is valued at kr68.60 at 02:20 EST, way below its 52-week high of kr80.00 and way higher than its 52-week low of kr36.00.
Volume
Today’s last reported volume for ZALARIS is 3759 which is 17.88% below its average volume of 4578.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.1%, now sitting on 1.19B for the twelve trailing months.
More news about ZALARIS.
3. BOUVET (BOUV.OL)
9.7% sales growth and 60.9% return on equity
Bouvet ASA provides IT and digital communication consultancy services for public and private sector companies in Norway, Sweden, and internationally. The company was incorporated in 1995 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, BOUVET has a trailing twelve months EPS of kr3.48.
PE Ratio
BOUVET has a trailing twelve months price to earnings ratio of 19.51. Meaning, the purchaser of the share is investing kr19.51 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 60.9%.
More news about BOUVET.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 23.89% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.54.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.86. Meaning, the purchaser of the share is investing kr17.86 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.89%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.6%, now sitting on 440.62M for the twelve trailing months.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr27.50 at 02:20 EST, below its 52-week high of kr28.80 and way higher than its 52-week low of kr20.60.
More news about VISTIN PHARMA.
